Table 2.

Descriptive characteristics of BCVA and OCT-parameters regarding iERM stage at baseline and during follow-up

iERM	Parameter	Baseline	3 Months	6 Months	12 Months	P-value
Stage II (n = 13)	BCVA	0.48 ± 0.19	0.35 ± 0.28	0.32 ± 0.28	0.29 ± 0.34	0.107 *
	CRT (µm)	423.85 ± 67.04	425.85 ± 104.98	373 ± 72.26	352 ± 78.85	0.009 †
	ONL (µm)	268.23 ± 81.21	220.15 ± 144.78	156.85 ± 61.13	153.92 ± 71.07	0.006 *
	EIFL (µm)	0	71.31 ± 75.82	69.23 ± 78.87	46.15 ± 48.33	0.008 *
	ME	13	12	8	4	n.p. ‡
	EZD	7	12	9	7	1.000 ‡
	CBA	1	1	0	0	n.p. ‡
	SRF	1	0	1	1	1.000 ‡
Stage III (n = 32)	BCVA	0.55 ± 0.36	0.45 ± 0.27	0.39 ± 0.28	0.32 ± 0.22	< 0.001 *
	CRT (µm)	492.22 ± 89.87	437.34 ± 107.64	427.00 ± 113.39	382 ± 82	< 0.001 †
	ONL (µm)	213.31 ± 66.48	199.06 ± 65.35	194.25 ± 64.14	175.69 ± 72.38	0.016 †
	EIFL (µm)	181.47 ± 109.66	115.41 ± 115.42	120.81 ± 99.82	83.94 ± 67.27	< 0.001 †
	ME	32	27	25	16	n.p. ‡
	EZD	24	29	27	21	0.508 ‡
	CBA	4	1	0	1	0.250 ‡
	SRF	5	3	2	1	0.219 ‡
Stage IV (n = 5)	BCVA	0.94 ± 0.15	0.70 ± 0.27	0.58 ± 0.22	0.42 ± 0.15	0.015 †
	CRT (µm)	633.40 ± 153.25	511.40 ± 91.55	484.60 ± 122.50	419.80 ± 113.33	0.09 †
	ONL (µm)	248.40 ± 120.52	213.80 ± 61.72	194.60 ± 57.79	168.60 ± 50.36	0.234 †
	EIFL (µm)	293.00 ± 170.25	214.00 ± 100.20	219.40 ± 124.36	168.20 ± 113.52	0.234 †
	ME	5	5	5	4	n.p. ‡
	EZD	5	5	5	5	n.p. ‡
	CBA	0	0	0	0	n.p. ‡
	SRF	2	1	1	0	n.p. ‡

*: Wilcoxon test; †: paired t-test, ‡: McNemar test, n.p.: test not executable due to assumptions violation or small sample size. BCVA: best corrected visual acuity, CRT: central foveal thickness, ONL: outer nuclear layer thickness, EIFL: ectopic inner foveal layer thickness, ME: macular edema, EZD: presence of ellipsoid zone defects, CBA: central bouquet abnormalities, SRF: presence of subretinal fluid